New Triple Combination Therapy in Newly Diagnosed Type 2 Diabetes

NCT07635953 on ClinicalTrials.gov · last registry update 2026-06-09

Registered but not yet open, with 296 participants planned. Due to report 1 July 2029, alongside 12 other tracked readouts that quarter. Primary outcome, as filed: Diabetic remission rate. Sponsors move these dates routinely; any movement since this site started watching is listed below. tirzepatide is approved in the US, but not for diabetes — a registration here is not an approval, and most drugs tested in a new condition never get one for it.

Status: NOT_YET_RECRUITING
Phase: P3
Drug: tirzepatide
Mounjaro, Zepbound
Sponsor: Sun Yat-sen University
Sponsor type: Other
Enrollment: 296
Started: 2026-07-01
Primary completion: 2029-07-01 estimated

Observed history

No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.

Primary outcome

Diabetic remission rate

Conditions studied

Diabetes Mellitus

Every field above is taken directly from the registry record. See all detected changes across the class, or the tirzepatide page for this molecule’s full trial and approval history.